{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T02:08:30Z","timestamp":1783908510653,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s00210-026-05291-z","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T02:11:02Z","timestamp":1775787062000},"page":"14141-14156","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Regulatory patterns of antibody-dependent cellular phagocytosis\u2013related genes in triple-negative breast cancer: An integrated multi-omics and single-cell analysis"],"prefix":"10.1007","volume":"399","author":[{"given":"Guihua","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanyue","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowen","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changqing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludan","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyue","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"5291_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1349-1","volume":"18","author":"D Aran","year":"2017","unstructured":"Aran D, Hu Z, Butte AJ (2017) xCell: digitally portraying the tissue cellular heterogeneity landscape. Genome Biol 18:220","journal-title":"Genome Biol"},{"key":"5291_CR2","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abl9171","volume":"8","author":"X Cao","year":"2022","unstructured":"Cao X, Chen J, Li B, Dang J, Zhang W, Zhong X, Wang C, Raoof M, Sun Z, Yu J et al (2022) Promoting antibody-dependent cellular phagocytosis for effective macrophage-based cancer immunotherapy. Sci Adv 8:eabl9171","journal-title":"Sci Adv"},{"key":"5291_CR3","unstructured":"Carlson M, Falcon S, Pages\u00a0 H, Li N (2019) org. Hs. eg. db: Genome wide annotation for Human. R package version 3, no. 2:3"},{"key":"5291_CR4","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E et al (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396:1817\u20131828","journal-title":"Lancet"},{"key":"5291_CR5","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486:346\u2013352","journal-title":"Nature"},{"key":"5291_CR6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan F, Reis-Filho JS (2022) Pathogenesis of triple-negative breast cancer. Annu Rev Pathol 17:181\u2013204","journal-title":"Annu Rev Pathol"},{"key":"5291_CR7","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1093\/glycob\/cwad078","volume":"33","author":"JSA D\u00edaz de Le\u00f3n","year":"2023","unstructured":"D\u00edaz de Le\u00f3n JSA, Aguilar I, Barb AW (2023) Macrophage N-glycan processing inhibits antibody-dependent cellular phagocytosis. Glycobiology 33:1182\u20131192","journal-title":"Glycobiology"},{"key":"5291_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810312","volume":"23","author":"J Feng","year":"2022","unstructured":"Feng J, Ren J, Li X, Zhang X, Yang Q, Wu Z, Cui L, Liao L, Gong Y, Cao D (2022) Phagocytosis-regulators-based signature to predict the prognosis and chemotherapy resistance for breast cancer patients. Int J Mol Sci 23:10312","journal-title":"Int J Mol Sci"},{"key":"5291_CR9","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1177\/2040620715622613","volume":"7","author":"L Gabellier","year":"2016","unstructured":"Gabellier L, Cartron G (2016) Obinutuzumab for relapsed or refractory indolent non-Hodgkin\u2019s lymphomas. Ther Adv Hematol 7:85\u201393","journal-title":"Ther Adv Hematol"},{"key":"5291_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0107468","volume":"9","author":"P Geeleher","year":"2014","unstructured":"Geeleher P, Cox N, Huang RS (2014) pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One 9:e107468","journal-title":"PLoS One"},{"key":"5291_CR11","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41587-023-01767-y","volume":"42","author":"Y Hao","year":"2024","unstructured":"Hao Y, Stuart T, Kowalski MH, Choudhary S, Hoffman P, Hartman A, Srivastava A, Molla G, Madad S, Fernandez-Granda C et al (2024) Dictionary learning for integrative, multimodal and scalable single-cell analysis. Nat Biotechnol 42:293\u2013304","journal-title":"Nat Biotechnol"},{"issue":"9","key":"5291_CR12","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1111\/cas.14116","volume":"110","author":"T Inao","year":"2019","unstructured":"Inao T, Kotani H, Iida Y, Kartika ID, Okimoto T, Tanino R, Shiba E, Harada M (2019) Different sensitivities of senescent breast cancer cells to immune cell-mediated cytotoxicity. Cancer Sci 110(9):2690\u20132699","journal-title":"Cancer Sci"},{"key":"5291_CR13","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1038\/s41586-021-03879-4","volume":"597","author":"RA Kamber","year":"2021","unstructured":"Kamber RA, Nishiga Y, Morton B, Banuelos AM, Barkal AA, Vences-Catal\u00e1n F, Gu M, Fernandez D, Seoane JA, Yao D et al (2021) Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597:549\u2013554","journal-title":"Nature"},{"key":"5291_CR14","doi-asserted-by":"publisher","first-page":"D353","DOI":"10.1093\/nar\/gkw1092","volume":"45","author":"M Kanehisa","year":"2017","unstructured":"Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K (2017) KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res 45:D353\u2013D361","journal-title":"Nucleic Acids Res"},{"key":"5291_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-143","volume":"11","author":"KJ Kao","year":"2011","unstructured":"Kao KJ, Chang KM, Hsu HC, Huang AT (2011) Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization. BMC Cancer 11:143","journal-title":"BMC Cancer"},{"key":"5291_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM (2020) Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw 18:479\u2013489","journal-title":"J Natl Compr Canc Netw"},{"key":"5291_CR17","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1158\/2326-6066.CIR-23-0389","volume":"12","author":"DA Knorr","year":"2024","unstructured":"Knorr DA, Blanchard L, Leidner RS, Jensen SM, Meng R, Jones A, Ballesteros-Merino C, Bell RB, Baez M, Marino A et al (2024) Fc\u03b3RIIB is an immune checkpoint limiting the activity of treg-targeting antibodies in the tumor microenvironment. Cancer Immunol Res 12:322\u2013333","journal-title":"Cancer Immunol Res"},{"issue":"7","key":"5291_CR18","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv073","volume":"107","author":"AV Lee","year":"2015","unstructured":"Lee AV, Oesterreich S, Davidson NE (2015) MCF-7 cells - changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst 107(7):djv073","journal-title":"J Natl Cancer Inst"},{"key":"5291_CR19","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1182\/blood.2023021088","volume":"143","author":"L Lenk","year":"2024","unstructured":"Lenk L, Baccelli I, Laqua A, Heymann J, Reimer C, Dietterle A, Winterberg D, Mary C, Corallo F, Taurelle J et al (2024) The IL-7R antagonist lusvertikimab reduces leukemic burden in xenograft ALL via antibody-dependent cellular phagocytosis. Blood 143:2735\u20132748","journal-title":"Blood"},{"key":"5291_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP (2023) Advances in systemic therapies for triple negative breast cancer. BMJ 381:e071674","journal-title":"BMJ"},{"key":"5291_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2020.120601","volume":"268","author":"H Li","year":"2021","unstructured":"Li H, Somiya M, Kuroda S (2021) Enhancing antibody-dependent cellular phagocytosis by re-education of tumor-associated macrophages with resiquimod-encapsulated liposomes. Biomaterials 268:120601","journal-title":"Biomaterials"},{"key":"5291_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01341-0","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Zhang H, Merkher Y, Chen L, Liu N, Leonov S, Chen Y (2022) Recent advances in therapeutic strategies for triple-negative breast cancer. J Hematol Oncol 15:121","journal-title":"J Hematol Oncol"},{"key":"5291_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2024.111150","volume":"119","author":"L Liu","year":"2024","unstructured":"Liu L, Li C, Yu L, Wang Y, Pan X, Huang J (2024) Deciphering the role of SMARCA4 in cardiac disorders: insights from single-cell studies on dilated cardiomyopathy and coronary heart disease. Cell Signal 119:111150","journal-title":"Cell Signal"},{"key":"5291_CR24","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1101\/gr.239244.118","volume":"28","author":"A Mayakonda","year":"2018","unstructured":"Mayakonda A, Lin DC, Assenov Y, Plass C, Koeffler HP (2018) Maftools: efficient and comprehensive analysis of somatic variants in cancer. Genome Res 28:1747\u20131756","journal-title":"Genome Res"},{"key":"5291_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/gb-2011-12-4-r41","volume":"12","author":"CH Mermel","year":"2011","unstructured":"Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G (2011) GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 12:R41","journal-title":"Genome Biol"},{"key":"5291_CR26","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1038\/nmeth.3337","volume":"12","author":"AM Newman","year":"2015","unstructured":"Newman AM, Liu CL, Green MR, Gentles AJ, Feng W, Xu Y, Hoang CD, Diehn M, Alizadeh AA (2015) Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 12:453\u2013457","journal-title":"Nat Methods"},{"key":"5291_CR27","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, Smyth GK (2015) Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43:e47","journal-title":"Nucleic Acids Res"},{"key":"5291_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01785-x","volume":"26","author":"C Scheffges","year":"2024","unstructured":"Scheffges C, Devy J, Giustiniani J, Francois S, Cartier L, Merrouche Y, Foussat A, Potteaux S, Bensussan A, Marie-Cardine A (2024) Identification of CD160-TM as a tumor target on triple negative breast cancers: possible therapeutic applications. Breast Cancer Res 26:28","journal-title":"Breast Cancer Res"},{"key":"5291_CR29","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, Gable AL, Fang T, Doncheva NT, Pyysalo S et al (2023) The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res 51:D638\u2013D646","journal-title":"Nucleic Acids Res"},{"key":"5291_CR30","doi-asserted-by":"publisher","first-page":"D330","DOI":"10.1093\/nar\/gky1055","volume":"47","author":"The Gene Ontology Consortium","year":"2019","unstructured":"The Gene Ontology Consortium (2019) The Gene Ontology Resource: 20 years and still GOing strong. Nucleic Acids Res 47:D330\u2013D338","journal-title":"Nucleic Acids Res"},{"key":"5291_CR31","unstructured":"Therneau T (2024)\u00a0A Package for Survival Analysis in R. 2024. R package version 3.8\u20133. https:\/\/CRAN.R-project.org\/package=survival. Accessed 3 Sept 2025"},{"key":"5291_CR32","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas A, Teicher BA, Hassan R (2016) Antibody-drug conjugates for cancer therapy. Lancet Oncol 17:e254\u2013e262","journal-title":"Lancet Oncol"},{"key":"5291_CR33","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.131882","volume":"4","author":"LC Tsao","year":"2019","unstructured":"Tsao LC, Crosby EJ, Trotter TN, Agarwal P, Hwang BJ, Acharya C, Shuptrine CW, Wang T, Wei J, Yang X et al (2019) CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis. JCI Insight 4:e131882","journal-title":"JCI Insight"},{"key":"5291_CR34","doi-asserted-by":"publisher","first-page":"4014","DOI":"10.18632\/aging.205575","volume":"16","author":"L Wang","year":"2024","unstructured":"Wang L, Li M, Yang H, Dai F, Xie N, Li L, Zhu M, Ding R (2024) Subtype recognition and identification of a prognosis model characterized by antibody-dependent cell phagocytosis-related genes in breast cancer. Aging 16:4014\u20134032","journal-title":"Aging"},{"key":"5291_CR35","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1056\/NEJMe2207681","volume":"387","author":"A Whone","year":"2022","unstructured":"Whone A (2022) Monoclonal antibody therapy in Parkinson\u2019s disease - the end? N Engl J Med 387:466\u2013467","journal-title":"N Engl J Med"},{"key":"5291_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: elegant graphics for data analysis","author":"H Wickham","year":"2016","unstructured":"Wickham H (2016) ggplot2: elegant graphics for data analysis. Springer-Verlag New York"},{"key":"5291_CR37","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, Feng T, Zhou L, Tang W, Zhan L et al (2021a) ClusterProfiler 4.0: a universal enrichment tool for interpreting omics data. Innovation 2:100141","journal-title":"Innovation"},{"key":"5291_CR38","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","volume":"53","author":"SZ Wu","year":"2021","unstructured":"Wu SZ, Al-Eryani G, Roden DL, Junankar S, Harvey K, Andersson A, Thennavan A, Wang C, Torpy JR, Bartonicek N et al (2021b) A single-cell and spatially resolved atlas of human breast cancers. Nat Genet 53:1334\u20131347","journal-title":"Nat Genet"},{"key":"5291_CR39","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, Edelman EJ, Lightfoot H, Forbes S, Bindal N, Beare D, Smith JA, Thompson IR et al (2013) Genomics of drug sensitivity in cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res 41:D955\u2013D961","journal-title":"Nucleic Acids Res"},{"key":"5291_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005199","volume":"10","author":"M Yang","year":"2022","unstructured":"Yang M, Mahanty A, Jin C, Wong ANN, Yoo JS (2022a) Label-free metabolic imaging for sensitive and robust monitoring of anti-CD47 immunotherapy response in triple-negative breast cancer. J Immunother Cancer 10:e005199","journal-title":"J Immunother Cancer"},{"key":"5291_CR41","doi-asserted-by":"publisher","DOI":"10.1172\/JCI153454","volume":"132","author":"B Yang","year":"2022","unstructured":"Yang B, Zhang Z, Chen X, Wang XY, Qin S, Du L, Yang C, Zhu L, Sun W, Zhu Y et al (2022b) An Asia-specific variant of human IgG1 represses colorectal tumorigenesis by shaping the tumor microenvironment. J Clin Invest 132:e153454","journal-title":"J Clin Invest"},{"key":"5291_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3612","volume":"4","author":"K Yoshihara","year":"2013","unstructured":"Yoshihara K, Shahmoradgoli M, Mart\u00ednez E, Vegesna R, Kim H, Torres-Garcia W, Trevi\u00f1o V, Shen H, Laird PW, Levine DA et al (2013) Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 4:2612","journal-title":"Nat Commun"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05291-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-026-05291-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-026-05291-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T01:43:13Z","timestamp":1783906993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-026-05291-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["5291"],"URL":"https:\/\/doi.org\/10.1007\/s00210-026-05291-z","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"23 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors approved the publication of the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}}]}}